Last reviewed · How we verify
Post radiotherapy commencement of anastrozole
Post radiotherapy commencement of anastrozole is a Aromatase inhibitor Small molecule drug developed by Trans Tasman Radiation Oncology Group. It is currently in Phase 3 development for Early-stage hormone receptor-positive breast cancer, adjuvant therapy post-radiotherapy in postmenopausal women. Also known as: Arimidex.
Anastrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer.
Anastrozole is an aromatase inhibitor that blocks the conversion of androgens to estrogen, reducing estrogen levels in postmenopausal women with hormone receptor-positive breast cancer. Used for Early-stage hormone receptor-positive breast cancer, adjuvant therapy post-radiotherapy in postmenopausal women.
At a glance
| Generic name | Post radiotherapy commencement of anastrozole |
|---|---|
| Also known as | Arimidex |
| Sponsor | Trans Tasman Radiation Oncology Group |
| Drug class | Aromatase inhibitor |
| Target | Aromatase (CYP19A1) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anastrozole selectively inhibits the aromatase enzyme, which catalyzes the final step of estrogen synthesis in postmenopausal women. By reducing circulating estrogen levels, it suppresses the growth of estrogen-dependent breast cancer cells. In this trial context, it is being evaluated as adjuvant therapy initiated after radiotherapy completion in early-stage breast cancer.
Approved indications
- Early-stage hormone receptor-positive breast cancer, adjuvant therapy post-radiotherapy in postmenopausal women
Common side effects
- Hot flashes
- Arthralgia/joint pain
- Fatigue
- Vaginal dryness
- Osteoporosis/bone loss
- Elevated cholesterol
Key clinical trials
- STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing) (PHASE3)
- Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT) (PHASE4)
- Study of Arimidex and Radiotherapy Sequencing (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Post radiotherapy commencement of anastrozole CI brief — competitive landscape report
- Post radiotherapy commencement of anastrozole updates RSS · CI watch RSS
- Trans Tasman Radiation Oncology Group portfolio CI
Frequently asked questions about Post radiotherapy commencement of anastrozole
What is Post radiotherapy commencement of anastrozole?
How does Post radiotherapy commencement of anastrozole work?
What is Post radiotherapy commencement of anastrozole used for?
Who makes Post radiotherapy commencement of anastrozole?
Is Post radiotherapy commencement of anastrozole also known as anything else?
What drug class is Post radiotherapy commencement of anastrozole in?
What development phase is Post radiotherapy commencement of anastrozole in?
What are the side effects of Post radiotherapy commencement of anastrozole?
What does Post radiotherapy commencement of anastrozole target?
Related
- Drug class: All Aromatase inhibitor drugs
- Target: All drugs targeting Aromatase (CYP19A1)
- Manufacturer: Trans Tasman Radiation Oncology Group — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Early-stage hormone receptor-positive breast cancer, adjuvant therapy post-radiotherapy in postmenopausal women
- Also known as: Arimidex
- Compare: Post radiotherapy commencement of anastrozole vs similar drugs
- Pricing: Post radiotherapy commencement of anastrozole cost, discount & access